drugset / Trial / NCT05789030
Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement
RandomizedParallel-groupOpen-labelTreatment
Summary
This study has been designed as a 12-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in IgG4-RD patients with superficial organ involvement: prednisone plus iguratimod and prednisone plus leflunomide.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2026-04-30
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iguratimod | Small molecule | 25 mg | — |
| Subject | Leflunomide | Small molecule | 10 mg | — |
| Subject | Leflunomide | Small molecule | 20 mg | — |
| Background | Prednisone | Other / unclassified | 5 mg | — |